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Abstract
Purpose Adjuvant systemic 5-fluorouracil (5-FU)-based che-
motherapy improves survival after resection of synchronous
colorectal liver metastases (CLMs), but not metachronous.We
retrospectively examined if adjuvant chemotherapy with new
regimen containing oxaliplatin or irinotecan improved sur-
vivals after resection of metachronous CLMs.
Methods Between 2000 and 2007, 52 patients having under-
taken resection ofmetachronous CLMswith curative intent were
identified from Taipei Veterans General Hospital hospitalization
registry. One patient with perioperative mortality and another
being lost to follow-up within 3 months after metastasectomy
were excluded. Thirty-one patients experienced six to 12 cycles
of FOLFOX or FOLFIRI chemotherapy while 19 patients with
5-FU/leucovorin (LV)-based chemotherapy following CLM
resection. The primary end point was disease-free survival
(DFS) and secondary end point, overall survival (OS).
Results By the univariate analysis, median DFS was
34.3 months in the FOLFOX/FOLFIRI group vs
14.2 months in the 5-FU/LV group (P=0.022). The median
OS and 5-year survival rates were longer than 57.7 months
(not reached, with median follow-up of 35.5 months) and
54.0%, respectively, in the FOLFOX/FOLFIRI group
compared to 49 months and 34.6% in the 5-FU/LV group
(P=0.027). FOLFOX/FOLFIRI chemotherapy was shown
by multivariate analyses to be an independent factor
predicting a better DFS (hazard ratio [HR]=0.37; 95% CI:
0.15–0.94; P=0.036) and a better OS (HR=0.27; 95% CI:
0.083–0.86, P=0.026) than 5-FU/LV-based.
Conclusions Adjuvant FOLFOX/FOLFIRI chemotherapy
following resection of metachronous CLMs is demonstrated
to have better DFS and OS than 5-FU/LV chemotherapy.
Keywords Adjuvant chemotherapy . Colorectal liver
metastasis . Irinotecan .Metachronous . Oxaliplatin
Introduction
The liver is the major metastatic site of colorectal cancers
(CRCs) and is often the only organ affected [1]. Surgical
resection has been an effective way to treat colorectal liver
metastases (CLMs) and may lead to a hopeful long-term
survival [2–6]. Survival benefit of CLM resection has been
established with the reported 5-year survival rates ranging
from 30% to 65% [2–6]. Among the many factors affecting
the outcome of metastasectomy of CLMs, adjuvant chemo-
therapy appears to have potential impact on survivals of
patients with CLMs after resection [7].
While systemic chemotherapy is frequently administered
after resection of metastases, the optimal regimen remains to
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be determined [8–11]. Adjuvant chemotherapy with 5-
fluorouracil (5-FU) and leucovorin (LV) after resection of
CLMs has been demonstrated to significantly benefit
disease-free survival (DFS) but not overall survival (OS)
[7, 9, 11]. Since more advanced oxaliplatin- and irinotecan-
containing chemotherapies have established their roles in
improving survival of patients with metastatic CRCs and
also patients with stage II and III CRCs [12, 13], they may
have a role in improving DFS or even OS in the adjuvant
setting following metastasectomy of CLMs. Nonetheless,
postoperative or perioperative adjuvant chemotherapy using
oxaliplatin-containing regimens was demonstrated to have
benefit in DFS but not in OS, or left OS not surveyed [7, 10,
14]. Since 5-FU-based chemotherapy following liver meta-
stasectomy improved OS only in the synchronous group but
not metachronous [15] and since most of the aforementioned
data were based on heterogeneous population either with
synchronous or metachronous CLMs, a possibility is thus
raised that significant survival benefit of patients with
metachronous CLMs after metastasectomy may need ad-
vanced adjuvant chemotherapy like oxaliplatin- or
irinotecan-containing chemotherapy.
With the current surgery and adjuvant chemotherapy, 5-year
survival rates of stage II and III CRCs range from 67% to 73%
[12]. Most of their survival failure comes from metastases.
Patients with an initial stage II or III CRC followed by a
metachronous occurrence of CLMs are deemed to be able to
benefit from CLM resection if the CLMs are resectable;
however, the survival benefit from oxaliplatin- or irinotecan-
containing adjuvant chemotherapy after resection of CLMs
has not been established. We analyzed herein the impact of
oxaliplatin- or irinotecan-containing adjuvant chemotherapy
compared to that of 5-FU/LV-based chemotherapy on
survival following resection of metachronous CLMs.
Patients and methods
Identification of eligible patients
Fifty-two consecutive patients were identified from hospitali-
zation registry of Taipei Veterans General Hospital, Taiwan
between January 1, 2000 and June, 2007 with a primary
diagnosis of colorectal cancer, had their initial metachronous
CLMs (diagnosis of CLMs >6 months after resection of
primary CRCs) resected, and were treated with postoperative
adjuvant chemotherapy. The CLMs were treated with a
curative intent. Patients with extrahepatic metastases or
macroscopic residual disease (R2 resection) were excluded.
However, patients with microscopic residual disease at
resection margin (R1) were allowed for recruitment. The size
of the largest metastatic lesions was measured as the largest
dimension on CT scan or MR imaging performed within
1 month prior to CLM treatment. The presence of microscopic
residual tumor was determined by pathology with cut margin
and lymphatic and vascular vessels in tumor-surrounding
tissue being examined.
Adjuvant chemotherapy
All patients identified had ever been treated with adjuvant
chemotherapy following liver metastasectomy surgery. They
were given 5-FU/LV-based regimens (FU5LV2 or modified
Mayo Clinc regimen [monthly 5-day bolus intravenous (IV) 5-
FU/LV]: 5-FU at 400 mg/m2/day and LVat 20 mg/m2/day, IV
injection from days 1 to 5 every 4 weeks for six cycles) [16,
17] or with FOLFOX or FOLFIRI [13, 17, 18] for six to 12
cycles. The assignment of patients into the two treatment
groups was at doctors’ discretion while to a significant extent
depending on the reimbursement of the government’s
insurance and probably with patients’ age being taken into
consideration. The majority of patients (20/26) identified after
2004 were treated with FOLFOX or FOLFIRI. Relatively
more patients at age >70 were in the 5-FU/LV group than in
the FOLFOX/FOLFIRI group (Table 1). When FOLFOX
was chosen, either FOLFOX4 or modified FOLFOX6
(oxaliplatin at 85 mg/m2 IV over 2 h, day1 plus LV at
400 mg/m2 IVover 2 h, plus 5-FU at 400 mg/m2 IV bolus on
day 1, then 2400 mg/m2 continuous infusion over 46–48 h)
was administrated [16, 19, 20]. FOLFIRI was administrated
as below: Irinotecan at 150–180 mg/m2 IVover 90 min, day1
plus LV at 400 mg/m2 IV infusion to match the duration of
irinotecan infusion plus 5-FU at 400 mg/m2 IV bolus on day
1, then 5-FU at 1200 mg/m2/day 2-day (total of 2400 mg/m2
over 46–48 h) continuous infusion [21]. Four patients had
been exposed previously to oxaliplatin- or irinotecan-
containing chemotherapy as adjuvant treatment after resection
of primary CRC tumor, but at least 6 months apart from the
studied adjuvant chemotherapy. CLMs were pathologically
proven after resection of CLMs.
Statistical evaluations
DFS was calculated from the date of resection of CLMs to
the date of proven recurrence, or death. For patients lost to
follow-up, data were censored on the date when the patient
was last seen alive without recurrence. OS was calculated
from the date of CLM resection until the date of death from
any cause. For patients lost to follow-up, data were
censored on the date when the patient was last seen alive.
DFS, OS, and 5-year survival rate were estimated by the
Kaplan–Meier method. The effect difference between
factors was determined by log-rank test. The factors
analyzed included age, gender, origin and stage of primary
tumor, maximum size of CLMs, number and distribution of
CLMs, time from resection of primary CRC to diagnosis of
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CLMs, serum CEA level at CLM resection, presence or
absence of microscopic residual disease at CLM resection
margin, and prior adjuvant FOLFOX or FOLFIRI chemo-
therapy following resection of primary tumor. Factors (age,
stage of primary CRC, time from surgery of primary CRC
to metastasis, CLM resection margin, and serum CEA at
metastasectomy) having impact on DFS with a P value less
than 0.1 in univariate analysis were recruited into the Cox
regression model. In addition, maximum size of CLMs,
number of CLMs, and time from surgery for primary CRC
to metastases were also recruited as variables in the Cox
proportional hazards regression models for they impacted
survival significantly as reported in previous investigations
[3, 22, 23]. Hazard ratios (HRs) were presented with their
95% confidence intervals (CIs). All statistical tests were
two-sided, and P<0.05 was considered statistically signif-
icant. All statistical analyses were performed using SPSS
17.0 (SPSS, Chicago, IL).
Results
Patients’ characteristics
Among the 52 patients identified for this study by
retrospective review of their medical records, one patient
Characteristic Adjuvant chemotherapy Total no. Pa
FU/LV no. (%) FOLFOX/FOLFIRI no. (%)
Total 19 (38) 31 (62) 50 (100)
Age (years)
≤70 6 (12) 20 (40) 26 (52) 0.04
>70 13 (26) 11 (22) 24 (48)
Gender
Male 13 (26) 21 (42) 34 (68) 1.0
Female 6 (12) 10 (20) 16 (32)
Primary tumor
Colon 10 (20) 24 (48) 33 (66) 0.12
Rectum 9 (18) 7 (14) 16(32)
Stage of primary CRC
II 8 (16) 11 (22) 19(38) 0.77
III 11 (22) 20 (40) 31 (62)
Maximum CLM size
≤3 cm 9 (18) 21 (42) 30 (60) 0.24
>3 cm 10 (20) 10 (20) 20 (40)
Number of CLMs
1 10 (20) 19 (38) 29 (58) 0.57
≥2 9 (18) 12 (24) 21 (42)
CLM distribution
Unilobar 13 (26) 27 (54) 40 (80) 0.15
Bilobar 6 (12) 4 (8) 10 (20)
Time from surgery of primary CRC to metastasis (months)
≤12 12 (24) 12 (24) 24 (48) 0.15
>12 7 (14) 19 (36.7) 26 (52)
CEA at metastasectomy (ng/ml)
≤50 14 (28) 25 (50) 39 (78) 0.73
>50 5 (10) 6 (12) 11 (22)
CLM resection margin
R0 resection 18 (36) 28 (56) 46 (92) 0.66
R1 resection 1 (2.0) 3 (6.0) 4 (8.0)
Prior FOLFOX/FOLFIRI following resection of primary CRC
Yes 0 (0) 4 (8) 4 (8) 0.15
No 19 (38) 27 (54) 46 (92)
Table 1 Demographic and
clinical characteristics of
patients with regard to adjuvant
chemotherapy following liver
metastasectomy
a P values were calculated with the
use of Pearson’s chi-square test
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was excluded from the analysis for perioperative mortality
and another for being lost to follow-up within 3 months
after metastasectomy. Thirty-one patients experienced six to
12 cycles of adjuvant FOLFOX or FOLFIRI chemotherapy
while 19 patients with six cycles of 5-FU/LV-based
chemotherapy following CLM resection.
The patients’ characteristics are shown in Table 1. The
median age is 70 years (range, 47 to 85 years). At the time
of analysis, six patients had died, seven patients were alive
with disease recurrence, and 17 patients were alive and
disease-free in the FOLFOX/FOLFIRI group. The
corresponding numbers in the 5-FU/LV group were eight,
six, and five patients, respectively. The median size of
liver metastases is 3 cm (1.2 to 8.1 cm). The number of
CLMs was one in 29 patients, two in 19 patients, and three
or more in two patients. High percentage of patients older
than 70 years is associated significantly with the 5-FU/LV
group (Table 1).
Adjuvant chemotherapy
Among the 31 patients in the FOLFOX/FOLFIRI group, six
patients received six cycles of FOLFOX, 11 received eight
to 12 cycles of FOLFOX, five patients received six cycles
of FOLFIRI, and nine patients received eight to 12 cycles
of FOLFIRI. In the 5-FU/LV-based group, ten patients
received six cycles of monthly 5-day bolus IV 5-FU/LV
while nine patients received 12-cycle chemotherapy with
FU5LV2 regimen. No chemotherapy death was recorded in
this study.
Fig. 1 Disease-free survival (a) and overall survival (b) according to
adjuvant chemotherapy following resection of colorectal liver metas-
tases. P by log-rank test








FU/LV 19 14.2 0.022
FOLFOX/FOLFIRI 31 34.3
Age (years)
<70 26 20.1 0.391
≥70 24 15.3
Gender
Male 34 18.9 0.647
Female 16 17.0
Primary tumor
Colon 34 18.9 0.768
Rectum 16 15.4
Stage of primary CRC
II 19 Not achieved (>33.0) 0.016
III 31 13.6
Maximum CLM size (cm)
≤3 30 13.6 0.693
>3 20 33.0
Number of CLMs
1 29 33.0 0.221
≥2 21 17.0
CLM distribution
Unilobar 40 33.0 0.335
Bilobar 10 15.3
Time from surgery of primary CRC to metastases (months)
≤12 24 11.8 0.036
>12 26 34.3
CLM resection margin
R0 resection 46 33.0 0.00
R1 resection 4 3.9
CEA at metastasectomy (ng/ml)
≤50 39 33.0 0.003
>50 11 9.0
Prior FOLFOX/FOLFIRI following resection of primary CRC
No 46 17.0 0.730
Yes 4 20.1
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Survival
The median follow-up time is 35.5 months (10.0 to
96 months). The median DFS was 34.3 months in the
FOLFOX/FOLFIRI group compared to 14.2 months in the
5-FU/LV group (Fig. 1a). Patients in the FOLFOX/
FOLFIRI group had a favorable risk of recurrence
compared to patients in the 5-FU/LV group both in
univariate (Table 2) and multivariate analyses (HR=0.37,
95% CI: 0.15– 0.94, P=0.036) (Table 3). The 3-year DFS
rates were 50.8% and 21.1% in the FOLFOX/FOLFIRI and
in the 5-FU/LV groups, respectively. The median OS in the
5-FU/LV group was 49 months and was not reached
(>57.7 months) as of the date of analysis in the FOLFOX/
FOLFIRI group. The 3-year and 5-year OS rates were
85.7% and 54.0%, respectively, in the FOLFOX/FOLFIRI
group vs 51.8% and 34.6% in the 5-FU/LV group (Fig. 1b).
By univariate analysis, adjuvant FOLFOX/FOLFIRI che-
motherapy (vs 5-FU/LV chemotherapy), stage II primary
CRC (vs stage III), negative CLM resection margin (R0
resection) (vs R1 resection) and ≤50 ng/ml of serum CEA
at metastasectomy predicted significantly favorable DFS
(Table 2). Adjuvant FOLFOX/FOLFIRI chemotherapy and
R0 resection of CLMs remained independently significant
to predict favorable DFS in the multivariate analysis, and
only adjuvant FOLFOX/FOLFIRI chemotherapy remained
the independent significant factor to predict favorable OS in
the multivariate analysis model (Table 3).
Discussion
Survival benefit from systemic adjuvant chemotherapy
using either 5-FU/LV-based or oxaliplatin- or irinotecan-
containing regimens following resection of CLMs has
never proven definitely [7, 9–11, 14]. Subgroup analyses
showed 5-FU-based chemotherapy as well as hepatic
arterial infusion (HAI) of floxuridine (FUDR) chemother-
apy following hepatectomy improved survival in the
synchronous group, but not metachronous [15]. Contrarily,
we have herein demonstrated both DFS and OS benefits
from systemic FOLFOX or FOLFIRI adjuvant chemother-
apy following resection of metachronous CLMs compared
with 5-FU/LV-based chemotherapy. Viewing that adjuvant
Table 3 Cox regression model of the adjuvant chemotherapy with regard to disease-free and overall survivals after liver metastasectomy
Multivariate analysis with regard to disease-free survival Multivariate analysis with regard to overall survival
Factor HR 95% CI P HR 95% CI P
Adjuvant chemotherapy
FU/LV 1 1
FOLFOX/FOLFIRI 0.37 0.15–0.94 0.036 0.27 0.083–0.86 0.026
Age (years)
≤70 1 1
>70 1.3 0.46–3.6 0.64 2.4 0.60–9.3 0.22
Stage of primary CRC
II 1 1
III 2.5 0.90–7.0 0.081 3.0 0.76–12 0.12
Maximum CLM size (cm)
>3 1 1
≤3 0.68 0.25–1.9 0.45 0.75 0.19–3.0 0.69
No. CLMs
1 1 1
≥2 1.2 0.47–2.8 0.76 0.81 0.24–2.7 0.73
Time from surgery of primary CRC to metastases (months)
≤12 1 1
>12 0.66 0.29–1.5 0.34 1.0 0.34–3.0 0.99
CLM resection margin
R0 resection 1 1
R1 resection 5.6 1.2–20 0.019 1.0 0.11–9.7 0.99
CEA at metastasectomy (ng/ml)
≤50 1 1
>50 1.8 0.70–4.8 0.21 2.1 0.59–7.3 0.25
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postoperative or perioperative oxaliplatin-containing che-
motherapy following liver metastasectomy has been shown
to result in better DFS, but not OS, than 5-FU/LV-based
chemotherapy [14], the most likely reason to explain the
discrepancy is that patients in our study were confined to
those with homogeneously metachronous CLMs instead of
those with both synchronous and metachronous CLMs as in
the other aforementioned studies. Whether patients with
synchronous CLMs can have additive survival benefit from
oxaliplatin- or irinotecan-containing adjuvant chemothera-
py is unknown, although they are shown to have survival
benefit from 5-FU/LV-based adjuvant chemotherapy [15].
Patients with metachronous CLMs are deemed to have
better prognosis than those with synchronous CLMs [3, 22,
24]; however, they were known to fail to have survival
benefit from 5-FU/LV-based adjuvant chemotherapy [15].
Seemingly, the better the prognosis the less the benefit can
be drawn from an adjuvant chemotherapy for CRCs [25].
Patient with metachronous CLMs may need oxaliplatin- or
irinotecan-containing adjuvant chemotherapy following
metastasectomy for a survival gain as shown in our study.
The significance of the association of patients’ character-
eristics with either adjuvant chemotherapy group was ana-
lyzed. As shown in Table 1, patients at age >70 years were
significantly higher in the 5-FU/LV group. However, this may
not affect the result that DFS of the 5-FU/LV group was
poorer than DFS of the FOLFOX/FOLFIRI group since there
is no DFS difference (P=0.39) between groups of age ≤70
and >70 in univariate analysis (Table 2), and also, age is not
an independent predictor for DFS or OS (Table 3).
R0 resection margin (vs R1 resection) was one indepen-
dent significant predictor for favorable DFS in addition to
FOLFOX/FOLFIRI adjuvant chemotherapy (vs 5-FU/LV-
based chemotherapy); however, it loses its independent
value to predict OS in the multivariate model. One reason
would be that the effect of the presence of microscopic
residual tumor on DFS was offset by the long-term effect of
FOLFOX/FOLFIRI chemotherapy in both the FOLFOX/
FOLFIRI and the 5-FU/LV groups once metastases recurred
after adjuvant chemotherapy.
We have demonstrated the improvement of DFS, and for
the first time, of OS by oxaliplatin- or irinotecan-containing
adjuvant chemotherapy following resection of metachronous
CLMs based on a single institute’s population. To further
confirm the results, prospective randomized trial is worth-
while. Given the high liver recurrence rate after metastasec-
tomy, combination of regional HAI FUDR with systemic
intravenous 5-FU has been shown to improve progression-
free survival and 2-year survival for patients after metastasec-
tomy, not specified for synchronous or metachronous CLMs
[26]. Deriving from our results, there is a potential to have
survival benefit if adjuvant oxaliplatin- or irinotecan-
containing therapy in combination with HAI FUDR is given
following metastasectomy of either synchronous or meta-
chronous CLMs. Actually, the potential has been demon-
strated in an NCCTG/NSABP trial [27].
Acknowledgements This study was supported by grant (DOH99-
TD-C-111-007) from the Center of Excellence for Cancer Research at
Taipei Veterans General Hospital, Taiwan and grant from the Taiwan
Clinical Oncology Research Foundation.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Stangl R, Altendorf-Hofmann A, Charnley RM et al (1994)
Factors influencing the natural history of colorectal liver metas-
tases. Lancet 343:1405–1410
2. Scheele J, Stangl R, Altendorf-Hofmann A et al (1995) Resection
of colorectal liver metastases. World J Surg 19:59–71
3. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for
predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg
230:309–318
4. Sugawara Y, Yamamoto J, Yamasaki S et al (2001) Estimating the
prognosis of hepatic resection in patients with metastatic liver
tumors from colorectal cancer with special concern for the timing
of hepatectomy. Surgery 129:408–413
5. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-
term survival following liver resection for hepatic colorectal
metastases. Ann Surg 235:759–766
6. Adam R, Pascal G, Azoulay D et al (2003) Liver resection for
colorectal metastases: the third hepatectomy. Ann Surg 238:871–883
7. Hebbar M, Pruvot FR, Romano O et al (2009) Integration of
neoadjuvant and adjuvant chemotherapy in patients with resect-
able liver metastases from colorectal cancer. Cancer Treat Rev
35:668–675
8. Kemeny MM, Adak S, Gray B et al (2002) Combined-modality
treatment for resectable metastatic colorectal carcinoma to the
liver: surgical resection of hepatic metastases in combination with
continuous infusion of chemotherapy—an intergroup study. J Clin
Oncol 20:1499–1505
9. Portier G, Elias D, Bouche O et al (2006) Multicenter randomized
trial of adjuvant fluorouracil and folinic acid compared with
surgery alone after resection of colorectal liver metastases: FFCD
ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982
10. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative
chemotherapy with FOLFOX4 and surgery versus surgery alone for
resectable liver metastases from colorectal cancer (EORTC intergroup
trial 40983): a randomised controlled trial. Lancet 371:1007–1016
11. Mitry E, Fields ALA, Bleiberg H et al (2008) Adjuvant
chemotherapy after potentially curative resection of metastases
from colorectal cancer: a pooled analysis of two randomized trials.
J Clin Oncol 26:4906–4911
12. André T, Boni C, Navarro M et al (2009) Improved overall
survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant
treatment in stage II or III colon cancer in the MOSAIC trial. J
Clin Oncol 27:3109–3116
13. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed
by FOLFOX6 or the reverse sequence in advanced colorectal
cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
1248 Int J Colorectal Dis (2010) 25:1243–1249
14. Kim SY, Kim HJ, Hong YS et al (2009) Resected colorectal liver
metastases: does the survival differ according to postoperative
chemotherapy regimen? J Surg Oncol 100:713–718
15. Wang X, Hershman DL, Abrams JA et al (2007) Predictors of
survival after hepatic resection among patients with colorectal
liver metastasis. Br J Cancer 97:1606–1612
16. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and
fluorouracil with or without oxaliplatin as first-line treatment in
advanced colorectal cancer. J Clin Oncol 18:2938–2947
17. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic
colorectal cancer: current options, current evidence. J Clin Oncol
23:4553–4560
18. de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial
comparing monthly low-dose leucovorin and fluorouracil bolus
with bimonthly high-dose leucovorin and fluorouracil bolus plus
continuous infusion for advanced colorectal cancer: a French
intergroup study. J Clin Oncol 15:808–815
19. Goldberg R, Sargent DJ, Morton RF et al (2004) A randomized
controlled trial of fluorouracil plus leucovorin, irinotecan, and
oxaliplatin combinations in patients with previously untreated
metastatic colorectal cancer. J Clin Oncol 22:23–30
20. Cheeseman S, Joel S, Chester J et al (2002) A “modified de
Gramont” regimen of fluorouracil, alone and with oxaliplatin, for
advanced colorectal cancer. Br J Cancer 87:393–399
21. Andre T, Louvet C (1999) Maindrault-Goebel F et al CPT-11
(irinotecan) addition to bimonthly, high-dose leucovorin and bolus
and continous-infusion 5-fluorouracil (FOLFIRI) for pretreated
metastatic colorectal cancer. Eur J Cancer 35:1343–1347
22. Merkel S, Bialecki D, Meyer T et al (2009) Comparison of clinical
risk scores predicting prognosis after resection of colorectal liver
metastases. J Surg Oncol 100:349–357
23. Bockhorn M, Sotiropoulos GC, Sgourakis G et al (2009) Major
liver resections in the elderly—is an aggressive approach
justified? Int J Colorectal Dis 24:83–86
24. Xu J, Wei Y, Zhong Y et al (2009) Hepatectomy for liver
metastasis of colorectal cancer. Int J Colorectal Dis 24:419–425
25. Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of
fluorouracil-based adjuvant therapy for stage II and III colon cancer:
who benefits and by how much? J Clin Oncol 22:1797–1806
26. Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial
infusion of chemotherapy after resection of hepatic metastases
from colorectal cancer. N Engl J Med 341:2039–2048
27. Alberts SR, Roh MS, Mahoney MR et al (2010) Alternating
systemic and hepatic artery infusion therapy for resected liver
metastases from colorectal cancer: a North Central Cancer
Treatment Group (NCCTG)/National Surgical Adjuvant Breast
and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-
66. J Clin Oncol 28:853–858
Int J Colorectal Dis (2010) 25:1243–1249 1249
